[go: up one dir, main page]

Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 11—November 2024
Dispatch

Dengue Outbreak Caused by Multiple Virus Serotypes and Lineages, Colombia, 2023–2024

Author affiliation: Yale University, New Haven, Connecticut, USA (N.D. Grubaugh); Rega Institute KU Leuven, Leuven, Belgium (N.D. Grubaugh); Yale School of Public Health, New Haven (N.D. Grubaugh, M.I. Breban, E. Bourgikos, V. Hill); Universidad del Valle, Cali, Colombia (D. Torres-Hernández, M.A. Murillo-Ortiz, I.C. Hurtado, E. López-Medina); Centro de Estudios en Infectología Pediátrica CEIP, Cali (D.M. Dávalos, P. Lopez, E. López-Medina); Valle del Cauca State Health Department, Cali (I.C. Hurtado); Clínica Imbanaco, Cali (E. López-Medina)

Cite This Article

Abstract

Dengue cases rose to record levels during 2023–2024. We investigated dengue in Valle del Cauca, Colombia, to determine if specific virus serotypes or lineages caused its large outbreak. We detected all 4 serotypes and multiple lineages, suggesting that factors such as climatic conditions were likely responsible for increased dengue in Colombia.

Reported cases of dengue caused by dengue virus (DENV) are increasing. DENV (genus Orthoflavivirus, family Flaviviridae) is composed of 4 genetically distinct serotypes, DENV-1–4. In 2023, a total of 4.6 million dengue cases were reported in the Americas, a record at the time and a 64% increase over 2022 (1). Those numbers were quickly surpassed in 2024, when almost 10 million dengue cases were reported through June (1). Of those cases, ≈8.4 million were from Brazil (1); however, many countries, including Colombia, reported large outbreaks. The Valle del Cauca State Health Department in Colombia reported ≈56,000 dengue cases through May 2024, compared with ≈23,000 for all of 2023 and <5,000 in 2022.

The cause of the substantial increase in dengue cases is likely multifaceted. Warming temperatures caused by climate change increase the transmission potential and expand the geographic range of the primary mosquito vector, Aedes aegypti (2). Moreover, Indian Ocean surface temperature anomalies, especially El Niño events, are associated with dengue epidemics in the Northern and Southern Hemispheres (3). A strong El Niño–Southern Oscillation event occurred during 2023–2024, the first since 2015–2016 (Golden Gate Weather Services, https://ggweather.com/enso/oni.htm). Moreover, new DENV introductions, perhaps related to resumption of travel after the COVID-19 pandemic (4), could be reaching large susceptible populations. For example, DENV-3 was rarely detected in the Americas during the 10 years before an introduction into the Caribbean from Asia around 2021 (5,6). We investigated whether a specific DENV serotype or lineage contributed to the recent surge in cases in Valle del Cauca, Colombia.

The Study

Figure 1

Cases in a study of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. A) Monthly dengue cases reported by Valle del Cauca State Health Department in Colombia. Samples from confirmed dengue cases (n = 266) diagnosed at Hospital Universitario del Valle, Cali, Colombia. B) Number of cases per month by serotype during 2023–2024 period of increased dengue outbreaks. Serotypes detected by quantitative reverse transcription PCR. Samples with viral levels below detection limit are labeled unknown. C) DENV lineage by amplicon-based sequencing listed by serotype, genotype, and lineage. DENV, dengue virus.

Figure 1. Cases in a study of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. A) Monthly dengue cases reported by Valle del Cauca State Health Department...

The Valle del Cauca State Health Department in Colombia reported 966 dengue cases in 2019, 655 in 2020, 8,940 in 2021, 4,630 in 2022, 22,988 in 2023, and 56,355 cases in 2024 (through May) (Figure 1, panel A). To determine which DENV serotypes and lineages were involved, we collected 150–500 µL of serum from all 266 confirmed dengue case-patients at Hospital Universitario del Valle (HUV) in Cali, Colombia, during April 2023–May 2024. Cases were diagnosed by VIDAS anti-DENV IgM and anti-DENV IgG (bioMérieux, https://www.biomerieux.com) assays at HUV. Patient ages were 0–77 (mean 16) years, and all participants signed an informed consent; parents or guardians signed for persons <18 years of age. HUV shipped samples to Yale University (New Haven, CT, USA) for molecular processing.

We used the QIAamp Viral RNA Mini Kit (QIAGEN, https://www.qiagen.com) to extract RNA from 140 µL of each serum sample. We initially determined DENV serotypes by using a multiplexed quantitative reverse transcription PCR (7) before attempting panserotype whole-genome amplicon sequencing with DengueSeq (8). We conducted bioinformatic analysis, including primer trimming and consensus sequence generation, by using a previously described iVar pipeline (8). We assigned DENV lineages to samples with >5% genome completeness, which was validated to be >93% accurate (9), by using the Dengue Virus Typing Tool nomenclature system (Genome Detective, https://www.genomedetective.com). We assigned serotypes to 185 (70%) samples (Figure 1, panel B); the assay was not able to detect serotypes in the remaining 81 samples because of low virus concentrations. Of the 185 samples with a serotype assignment, we assigned lineages to 171 (92%) samples via sequencing (Figure 1, panel C).

Among 2023–2024 samples, we detected all 4 DENV serotypes (DENV-1, 35; DENV-2, 85; DENV-3, 63; and DENV-4, 2) and 81 unknown serotypes (Figure 1, panel B). For part of 2023, we detected relatively equal proportions of DENV-1, DENV-2, and DENV-3, but then DENV-1 decreased as DENV-2 increased during late 2023 to early 2024. We also detected multiple lineages per serotype, except for DENV-4. DENV-3 genotype III lineage C.1 (3III_C.1 [9]), DENV-2III_D.2, DENV-2II_F.1.1.2, and DENV-1V_D.1 were most common (Figure 1, panel C).

To further investigate DENV lineages, we performed phylogenetic analysis using 79 sequenced samples for which we achieved >70% genome coverage: 10 DENV-1 sequences, 38 DENV-2 sequences, and 31 DENV-3 sequences. We combined our data with a background dataset downloaded from GenBank (Appendix Table) and then downsampled the data per serotype so that we kept all sequences from Colombia, 5 per year from the other countries in the Americas, and 1 per year from each country outside the Americas (1,007 DENV-1, 965 DENV-2, and 542 DENV-3 sequences). We analyzed the sequences using the Nextstrain bioinformatic and phylogenetic framework (10), and constructed maximum-likelihood trees using IQ-TREE (11) and a general time-reversible substitution model.

Figure 2

Time-resolved maximum-likelihood phylogeny of DENV-1 detected during an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-1 sequences downloaded from GenBank and was constructed by using IQ-TREE (http://www.iqtree.org). A) Full reconstruction of 1,007 DENV-1 sequences from 1944–2024 colored by sampling location. B) Detail of the DENV-1V_D clade highlighting sequences from Valle del Cauca, Colombia (black) from 2023 through mid-2024. DENV, dengue virus.

Figure 2. Time-resolved maximum-likelihood phylogeny of DENV-1 detected during an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-1 sequences downloaded...

Our DENV-1 phylogenetic analysis revealed cocirculation of 2 distinct lineages, DENV-1V_D.1 and D.2 (Figure 2). Both lineages were previously detected in Colombia and elsewhere in South America (5,12), representing ongoing local and regional lineage persistence and diversification for the past ≈15–20 years.

Figure 3

Time-resolved maximum-likelihood phylogeny of DENV-2 detected during an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-2 sequences downloaded from GenBank and was constructed by using IQ-TREE (http://www.iqtree.org). A) Full reconstruction of 965 DENV-2 sequences from 1964­–2024 colored by sampling location. B) Detail of the DENV-2III_D.2 clade highlighting sequences from Valle del Cauca, Colombia (black) from 2023 through mid-2024. C) Detail of DENV-2II_F.1.1.2 clades highlighting sequences from Valle del Cauca, Colombia (black) from 2023 through mid-2024. DENV, dengue virus.

Figure 3. Time-resolved maximum-likelihood phylogeny of DENV-2 detected during an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-2 sequences downloaded...

Our DENV-2 phylogenetic analysis presents a more complicated picture of 3 genetic clusters and 3 individual sequences dispersed among 2 defined lineages, DENV-2III_D.2 and DENV-2II_F.1.1.2 (Figure 3). Lineage 2III_D.2 is a descendent of the original DENV-2 genotype III (i.e., Asian-American lineage) that was introduced in the Americas during the late 1970s and subsequently became established throughout the region, including in Colombia (13). DENV-2 genotype II (a.k.a. Cosmopolitan lineage) was recently introduced into the Americas from Asia and was first detected during a dengue outbreak in Peru in 2019 (14). Detection of DENV-2II_F.1.1.2 in Valle del Cauca demonstrates that the emerging Cosmopolitan genotype can become established alongside the existing Asian-American genotype.

Figure 4

Time-resolved maximum-likelihood phylogeny of DENV-3 detected in an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-3 sequences downloaded from GenBank and was constructed by using IQ-TREE (http://www.iqtree.org). A) Full reconstruction of 542 DENV-3 sequences from 1964 through 2024 colored by sampling location. B) Detail of the DENV-3III_C.1 clade highlighting sequences from Valle del Cauca, Colombia (black) from 2023 through mid-2024.

Figure 4. Time-resolved maximum-likelihood phylogeny of DENV-3 detected in an investigation of multiple virus serotypes and lineages during dengue outbreak, Valle del Cauca, Colombia, 2023–2024. The tree includes global DENV-3 sequences downloaded...

One hypothesis for the sudden increase in dengue cases is the introduction and rapid spread of a new DENV-3 lineage from Asia (5). DENV-3 can go undetected for long time periods in the Americas, sometimes for more than a decade, leaving large portions of the population potentially susceptible to this serotype (4,6,15). Therefore, detection of an emerging DENV-3III_B.3.2 lineage in the Caribbean (5), Brazil (6), Nicaragua (4), and elsewhere in the Americas was alarming. We detected 1 dengue case from January 2024 in Valle del Cauca with a likely 3III_B.3.2 infection (18% genome coverage), but 97% (61/63) of DENV-3 infections were lineage 3III_C.1 (Figure 1, panel C), and the lineage from 1 DENV-3 infection could not be assigned. DENV-3III_C was likely first introduced into the Americas in the early 1990s (13). Our findings show that DENV-3III_C has persisted through long periods of low detection (Figure 4), including sporadic detections of 3III_C.1 in Colombia since the early 2000s. Therefore, our results suggest that populations in the Americas might be susceptible to DENV-3 in general and not just the emerging 3III_B.3.2 lineage.

Conclusions

We investigated DENV infections from Valle del Cauca, Colombia, to determine if a specific virus serotype or lineage might be driving the record number of dengue cases in that state (1). We detected all 4 serotypes and found DENV-1, DENV-2, and DENV-3 shared dominance and at least 8 separate defined lineages were involved. Those lineages included multiple DENV-1 genotype V and DENV-2 genotype III lineages that have circulated in the Americas for ≈40 years (13), as well as an emerging DENV-2 genotype lineage. Moreover, despite the rapid spread of a new DENV-3III_B.3.2 lineage in the Americas (46), we found that the dominant DENV-3 lineage was 3III_C.1, which has been sporadically detected in Colombia for ≈20 years. Although multiple DENV serotypes are often detected during endemic transmission, our results were unexpected because outbreaks are typically dominated by a single serotype.

In summary, DENV lineages can have variable phenotypes that affect virulence, transmissibility, and immune evasion. Detecting several co-dominating serotypes and lineages in Valle del Cauca suggests that the specific viruses were not the primary driver of the large outbreak. Our study demonstrates how genomic surveillance can help investigate causes of outbreaks and aid public health responses.

Dr. Grubaugh is an associate professor at the Yale School of Public Health in Connecticut, USA. His research interests focus on integrating genomic epidemiology in public health systems to enhance virus surveillance and outbreak response, with a special emphasis on arthropodborne viruses.

Top

Acknowledgments

Sequencing data are available at National Center for Biotechnology Information BioProject (https://www.ncbi.nlm.nih.gov/bioproject; accession no. PRJNA1132139). Alignments, trees, and Nextstrain outputs are available at https://github.com/grubaughlab/DENV-genomics/tree/master/paper_2024-CO.

This study was approved by the research ethics committee at Hospital Universitario del Valle and Yale University Human Research Protection Program (protocol no. 2000033281). This publication was made possible by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award no. DP2AI176740 to N.D.G. and an NIH Shared Equipment grant (no. 1S10OD028669-01) award to the Yale Center for Genome Analysis. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the NIH.

Top

References

  1. Pan American Health Organization, World Health Organization. Data—dengue [cited 2024 Jul 1]. https://www3.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en.html
  2. Messina  JP, Brady  OJ, Golding  N, Kraemer  MUG, Wint  GRW, Ray  SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4:150815. DOIPubMedGoogle Scholar
  3. Chen  Y, Xu  Y, Wang  L, Liang  Y, Li  N, Lourenço  J, et al. Indian Ocean temperature anomalies predict long-term global dengue trends. Science. 2024;384:63946. DOIPubMedGoogle Scholar
  4. Cerpas  C, Vásquez  G, Moreira  H, Juarez  JG, Coloma  J, Harris  E, et al. Introduction of new dengue virus lineages of multiple serotypes after COVID-19 pandemic, Nicaragua, 2022. Emerg Infect Dis. 2024;30:120313. DOIPubMedGoogle Scholar
  5. Taylor-Salmon  E, Hill  V, Paul  LM, Koch  RT, Breban  MI, Chaguza  C, et al. Travel surveillance uncovers dengue virus dynamics and introductions in the Caribbean. Nat Commun. 2024;15:3508. DOIPubMedGoogle Scholar
  6. Naveca  FG, Santiago  GA, Maito  RM, Ribeiro Meneses  CA, do Nascimento  VA, de Souza  VC, et al. Reemergence of dengue virus serotype 3, Brazil, 2023. Emerg Infect Dis. 2023;29:14824. DOIPubMedGoogle Scholar
  7. Santiago  GA, Vergne  E, Quiles  Y, Cosme  J, Vazquez  J, Medina  JF, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. PLoS Negl Trop Dis. 2013;7:e2311. DOIPubMedGoogle Scholar
  8. Vogels  CBF, Hill  V, Breban  MI, Chaguza  C, Paul  LM, Sodeinde  A, et al. DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus. BMC Genomics. 2024;25:433. DOIPubMedGoogle Scholar
  9. Hill  V, Cleemput  S, Pereira  JS, Gifford  RJ, Fonseca  V, Tegally  H, et al. A new lineage nomenclature to aid genomic surveillance of dengue virus. PLoS Biol. 2024;22:e3002834. DOIPubMedGoogle Scholar
  10. Hadfield  J, Megill  C, Bell  SM, Huddleston  J, Potter  B, Callender  C, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34:41213. DOIPubMedGoogle Scholar
  11. Minh  BQ, Schmidt  HA, Chernomor  O, Schrempf  D, Woodhams  MD, von Haeseler  A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:15304. DOIPubMedGoogle Scholar
  12. Carrillo-Hernandez  MY, Ruiz-Saenz  J, Jaimes-Villamizar  L, Robledo-Restrepo  SM, Martinez-Gutierrez  M. Phylogenetic and evolutionary analysis of dengue virus serotypes circulating at the Colombian-Venezuelan border during 2015-2016 and 2018-2019. PLoS One. 2021;16:e0252379. DOIPubMedGoogle Scholar
  13. Allicock  OM, Lemey  P, Tatem  AJ, Pybus  OG, Bennett  SN, Mueller  BA, et al. Phylogeography and population dynamics of dengue viruses in the Americas. Mol Biol Evol. 2012;29:153343. DOIPubMedGoogle Scholar
  14. García  MP, Padilla  C, Figueroa  D, Manrique  C, Cabezas  C. Emergence of the Cosmopolitan genotype of dengue virus serotype 2 (DENV2) in Madre de Dios, Peru, 2019. Rev Peru Med Exp Salud Publica. 2022;39:1268. DOIPubMedGoogle Scholar
  15. Santiago  GA, McElroy-Horne  K, Lennon  NJ, Santiago  LM, Birren  BW, Henn  MR, et al. Reemergence and decline of dengue virus serotype 3 in Puerto Rico. J Infect Dis. 2012;206:893901. DOIPubMedGoogle Scholar

Top

Figures

Top

Cite This Article

DOI: 10.3201/eid3011.241031

Original Publication Date: October 08, 2024

Table of Contents – Volume 30, Number 11—November 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Nathan D. Grubaugh, Yale School of Public Health, 60 College St, Ste 608, New Haven, CT 06510, USA

Send To

10000 character(s) remaining.

Top

Page created: September 18, 2024
Page updated: October 22, 2024
Page reviewed: October 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external